Research Report Screener Results

Chart, Financials, Historical Prices, Industry, Insider, Messages, Options, Profile, Reports, Research, SEC Filings, more...

Report Screener | Stock Screener | Bond Screener | Fund Screener

Report Search Results As of 10-Feb-2010
New Screen

All Reports | Brokerage Reports | Independent Reports

All Reports (Showing 1 to 10 of 35)

Release
Date Contributor Author Title Pages Price StarMine Author Rating More Info

EPS Accuracy * Portfolio Return **
9-Feb-10 New Constructs, LLC N/A BMRN: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings 19 $10 View Abstract
9-Feb-10 EconomicInvestor N/A "The Economy Matters" Report for BMRN: the economy's impact on BMRN's price and risk, featuring the powerful EconomicInvestor Star Rating 6 $15 View Abstract
8-Feb-10 Plunkett Research, Ltd. Jack W. Plunkett Biotechnology & Genetics Industry Market Research and Competitive Analysis 2010 569 $299 View Abstract
8-Feb-10 Plunkett Research, Ltd. Jack W. Plunkett Biotech & Genetics Industry Trends, Statistics & Analysis 2010 (Summary) 71 $199 View Abstract
7-Feb-10 Wright Reports N/A Wright Industry Averages: Health, Medicine and Pharmaceuticals (North America) 100 $169 View Abstract
7-Feb-10 Wright Reports N/A Wright Industry Averages: Health, Medicine and Pharmaceuticals (United States) 98 $169 View Abstract
7-Feb-10 TheStreet.com Ratings N/A TheStreet.com Ratings Stock Report For: BIOMARIN PHARMACEUTICAL INC 5 $25 View Abstract
5-Feb-10 Ford Investor Services, Inc. N/A Value Graph: BIOMARIN PHARM -- BMRN 1 $4 View Abstract
5-Feb-10 Ford Investor Services, Inc. N/A Industry Value Graph: BMRN , CRXL , NPSP , PGNX , RIGL , ZGEN -- DRUGS 3 $4 View Abstract
5-Feb-10 Jefferson Research N/A Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of BIOMARIN PHARMACEUTICAL INC including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation. 11 $20 View Abstract
Next 20

Brokerage Reports (Showing 1 to 9 of 9)

Release
Date Contributor Author Title Pages Price StarMine Author Rating More Info

EPS Accuracy * Portfolio Return **
26-Jan-10 Roth Capital Partners, Inc. Research Department Morning Call Summary 11 $25 View Abstract
25-Jan-10 Roth Capital Partners, Inc. Scott R. Henry CFA, Andrew Vaino PhD Prolor Presents Positive Preclinical Pharmacokinetic Primate IFN Data 4 $10 View Abstract
20-Jan-10 Thomson StreetEvents N/A BMRN - Event Transcript of BioMarin Pharmaceutical Inc. conference call, Jan. 11, 2010 / 11:00am ET 7 $75 View Abstract
13-Jan-10 Collins Stewart LLC Salveen J. Kochnover CFA Management Meeting; Near-Term Focus on GALNS Data in 2Q10 5 $10 View Abstract
6-Jan-10 Roth Capital Partners, Inc. Research Department Morning Call Summary 14 $50 View Abstract
6-Jan-10 Collins Stewart LLC Salveen J. Kochnover CFA Amifampridine Phosphate Approved in the E.U. 3 $10 View Abstract
6-Jan-10 Roth Capital Partners, Inc. Scott R. Henry CFA, Andrew Vaino PhD Amifampridine Approved In Europe As Expected 4 $10 View Abstract
4-Jan-10 Roth Capital Partners, Inc. Research Department Morning Call Summary 13 $50 View Abstract
4-Jan-10 Roth Capital Partners, Inc. Scott R. Henry CFA, Andrew Vaino PhD A 2010 Catalyst Calendar Of Roth Biotech Coverage 8 $25 View Abstract

Independent Reports (Showing 1 to 10 of 26)

Release
Date Contributor Author Title Pages Price More Info
9-Feb-10 New Constructs, LLC N/A BMRN: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings 19 $10 View Abstract
9-Feb-10 EconomicInvestor N/A "The Economy Matters" Report for BMRN: the economy's impact on BMRN's price and risk, featuring the powerful EconomicInvestor Star Rating 6 $15 View Abstract
8-Feb-10 Plunkett Research, Ltd. Jack W. Plunkett Biotechnology & Genetics Industry Market Research and Competitive Analysis 2010 569 $299 View Abstract
8-Feb-10 Plunkett Research, Ltd. Jack W. Plunkett Biotech & Genetics Industry Trends, Statistics & Analysis 2010 (Summary) 71 $199 View Abstract
7-Feb-10 Wright Reports N/A Wright Industry Averages: Health, Medicine and Pharmaceuticals (North America) 100 $169 View Abstract
7-Feb-10 Wright Reports N/A Wright Industry Averages: Health, Medicine and Pharmaceuticals (United States) 98 $169 View Abstract
7-Feb-10 TheStreet.com Ratings N/A TheStreet.com Ratings Stock Report For: BIOMARIN PHARMACEUTICAL INC 5 $25 View Abstract
5-Feb-10 Ford Investor Services, Inc. N/A Value Graph: BIOMARIN PHARM -- BMRN 1 $4 View Abstract
5-Feb-10 Ford Investor Services, Inc. N/A Industry Value Graph: BMRN , CRXL , NPSP , PGNX , RIGL , ZGEN -- DRUGS 3 $4 View Abstract
5-Feb-10 Jefferson Research N/A Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of BIOMARIN PHARMACEUTICAL INC including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation. 11 $20 View Abstract
Next 16

* EPS Accuracy is a measure of an analyst's ability to accurately estimate the EPS for a company.
** Portfolio Return is a measure of the performance of an analyst's recommendations relative to his peers.

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.